TEL AVIV, IL, Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - A2Z Cust2Mate Solutions Corp. ("A2Z") (NASDAQ:AZ)(FRA - WKN:A3CSQ), a global leader in innovative technology solutions, today announced it has signed global framework agreements with Nayax Capital, ("Nayax Capital"), whereby Nayax Capital will enable financing for the sale or lease of Cust2Mate smart carts enabled with Nayax’s complete solution.This announcement is further to the company’s press release on September 10, 2024 announcing the formation of a joint venture with Nayax Ltd. to mutually promote the sales of A2Z Cust2Mate’s smart cart solution integrated with Nayax’s payment solution for on-cart payments. The joint venture announcement can be read here.Under the terms of the framework agreements, Nayax Capital will enable retailers to pay or lease the Cust2Mate smart carts that are sold as part of a comprehensive solution, which includes Nayax’s payment, management and loyalty solution, in monthly installments. The framework agreements cover the A2Z Cust2Mate’s smart carts, charging solutions, and IT infrastructure upgrades, as needed, for customers around the world including Europe, North America and Latin America. Any financing extended is subject to individual terms and conditions and approval by Nayax Capital and is non-recourse to A2Z.Gadi Graus, CEO of A2Z, stated, “We have teamed up with Nayax Capital to help merchants grow by making it easier for retailers around the globe to adopt our smart cart solution. With a readily available financing option, approved retailers can move quickly to implement our smart carts and begin realizing tangible benefits to their operations and improve the shopping experience for their customers.”About A2Z Cust2Mate Solutions Corp.A2Z Cust2Mate Solutions Corp. brings innovation, ease, excitement and value to retailers and shoppers. The Company is transforming brick-and-mortar retail with innovative smart shopping cart solutions that digitize the in-store shopping experience. The proven-in-use, friendly, sensor rich, AI driven carts enhance customer satisfaction and loyalty, minimize shrinkage, optimize retailers' operations and enable new business models. The smart carts streamline in-store shopping by enabling in-cart scanning and payment, allowing users to bypass checkout lines while alleviating labor shortages. Retailers can optimize merchandising, store layouts and promotions from data-driven insights, while shoppers get real-time information and personalized offers, turning a necessary chore into a fun and rewarding experience.For more information on A2Z Cust2Mate Solutions Corp. (NASDAQ:AZ)($AZ)(FRA - WKN:A3CSQ) and its subsidiary, Cust2mate Ltd., please visit, please visit www.cust2mate.com.Cautionary Statement Regarding Forward-looking StatementsMatters discussed in this press release may contain forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including whether the referenced patent will be granted. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the Company's filings on EDGAR and with the SEC. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. Forward-looking statements contained in this announcement are made as of this date, and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein.About NayaxNayax is a global commerce enablement, payments and loyalty platform designed to help merchants scale their business. Nayax offers a complete solution including localized cashless payment acceptance, management suite, and loyalty tools, enabling merchants to conduct commerce anywhere, at any time. As a global leader in serving unattended retail, Nayax has transformed into a comprehensive solution focused on our customers’ growth across multiple channels. As of June 30, 2024, Nayax has 11 global offices, approximately 1,100 employees, connections to more than 80 merchant acquirers and payment method integrations and is globally recognized as a payment facilitator. Nayax’s mission is to improve its customers’ revenue potential and operational efficiency. For more information, please visit www.nayax.com.Issued By: Swan Consultancy Sdn. Bhd. on behalf of A2Z Cust2mate Solutions Corp. and Nayax Ltd.For more information, please contact:Mandy TanEmail: m.tan@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

ANKARA, Turkey, Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, has announced the positive results of its Phase 2 clinical trial evaluating the safety and efficacy of its investigational drug, GN-037 topical cream, in treating mild to moderate plaque psoriasis. The findings were presented at Amsterdam's European Academy of Dermatology and Venereology (EADV) 2024 Congress.GEN PharmaceuticalsGEN Pharmaceuticals Manufacturing FacilityThis multicenter, randomized, double-blind, placebo-controlled Phase 2 study involved 190 patients across 19 clinical centers in Türkiye. Patients were treated with GN-037, clobetasol 17-propionate, or placebo twice daily for four weeks, followed by an additional four-week observation period. The study demonstrated GN-037's statistically significant superiority in reducing psoriasis symptoms compared to placebo, positioning it as a promising new treatment option for psoriasis patients worldwide.Key Findings:The GN-037 Phase 2 trial met the primary endpoint: treatment success,defined as the percentage of patients with at least a 2-grade improvement in Investigator's Global Assessment (IGA) score and achieving an IGA score of 0 or 1.37.9% of patients treated with GN-037 achieved treatment success at week four compared to 9.1% in the placebo group (P=0.006).GN-037 demonstrated significant improvements in reducing erythema (57.6%, P=0.008), plaque elevation (72.7%, P=0.001), and scaling (80.3%, P=0.006) compared to placebo.31.8% of patients in the GN-037 group achieved at least a 75% reduction in PASI, compared to 6.1% in the placebo group (P=0.009).No new safety concerns emerged with similar treatment-emergent adverse events across all arms.Abidin Gülmüs, Chairman of GEN, stated: "We are thrilled to announce the positive results of our Phase 2 clinical trial. We believe GN-037 offers new hope for the global psoriasis community."Nadir Ulu, MD, PhD, Vice President of R&D, added: "Our Phase 2 trial results highlighted GN-037's potential to improve patient outcomes significantly, and it may provide a novel, well-tolerated treatment option for patients with mild to moderate plaque psoriasis."About GEN:Founded in 1998, GEN is Türkiye's leading speciality pharmaceutical company. It is focused on developing innovative therapies across multiple therapeutic areas, with significant R&D investments and a commitment to advancing global healthcare. GEN actively works in both in-licensing and out-licensing business models. GEN partners with leading global pharmaceutical companies to bring innovative therapies and rare solutions to communities in its countries. It also develops and produces highly demanded and competitive therapeutic products in its GMP-certified manufacturing facility to bring therapy solutions required in international markets.For more information, visit www.genilac.com.tr.For inquiries:Bulutay GÜNES, Head of Corporate Brand, b.gunes@genilac.comAli KETENCIOGLU, Investor Relations Manager, a.ketencioglu@genilac.comContact InformationBulutay GunesHead of Corporate Brandb.gunes@genilac.comAli KetenciogluInvestor Relations Managera.ketencioglu@genilac.comSOURCE: GEN Pharmaceuticals Copyright 2024 ACN Newswire via SeaPRwire.com.

SELANGOR, Malaysia, Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - OSK Property is excited to announce its partnership with PeopleUp, a leading multi-enrichment and play group founded in 2018 in Singapore. Together, they will introduce a brand-new regional play brand to Atria Shopping Gallery in Petaling Jaya, marking PeopleUp’s FIRST expansion beyond Singapore. This groundbreaking entertainment hub will cater to families and kids, creating a one-stop destination for fun, learning, and holistic family experiences.1. Ong Ju Xing, Deputy Group Managing Director, OSK Holdings Berhad2. Samantha Lew Pey Shin, General Manager, Group Retail Leasing, OSK Property Investment3. Chris Tan Wei Quan, Chief Executive Officer, PeopleUp4. Loh Wai Keong, Managing Director & Chief Executive Officer, Greenwillow Capital Management[L-R]The signing ceremony took place at Atria Shopping Gallery and the agreement was executed between OSK Property Investment, Group Retail Leasing General Manager Samantha Lew Pey Shin and PeopleUp Singapore Chief Executive Officer Chris Tan Wei Quan. The event was witnessed by OSK Group Deputy Group Managing Director Ong Ju Xing and Greenwillow Capital Management Managing Director Loh Wai Keong.PeopleUp has successfully set its footprint in Malaysia, thanks to its regional strategic partners, Arkwood Trustee (M) Berhad and Greenwillow Capital Management. These two companies are backed by key figures, Sunny Yeo, Chief Executive Officer and Managing Director of Arkwood Trustee, and Loh Wai Keong, Managing Director of Greenwillow.With over 16 thriving subsidiary brands in Singapore, PeopleUp has earned its reputation for delivering innovative, engaging, and memorable experiences for families. Its flagship brands, such as Bouncy Paradise - Asia’s largest inflatable playground - and Dinoland - Singapore’s first immersive and largest indoor dinosaur park with live forest, along with VroomTown, the first mega indoor drive-play city for kids, have welcomed over half a million visitors annually.Set to open in the first half of 2025, the new expansion will build upon this success, showcasing exciting, family-oriented concepts from Singapore and introducing new experiences tailored to the Malaysian market.OSK Property Investment Group Retail Leasing General Manager Samantha Lew said "At OSK Property, we are committed to curating spaces that bring value and excitement to the community. Partnering with PeopleUp is an exciting step forward in transforming Atria Shopping Gallery into a choice destination for families. This new play concept will enhance the mall’s position as a leading family-friendly venue, attracting visitors from across the region."Chris Tan Wei Quan, Chief Executive Officer of PeopleUp Singapore, expressed his enthusiasm for the expansion: "We are thrilled to bring our unique, holistic approach of family entertainment to Malaysia. The collaboration with OSK Property allows us to share our vision and passion for innovative play and enrichment with a wider audience. We are confident that this flagship will resonate with families and set a new benchmark for family entertainment in the region."Anchoring over 60,000 square feet within Atria Shopping Gallery, PeopleUp will see the creation of an exciting new flagship family destination that encapsulates a wide array of fun, entertainment, and learning experiences. The flagship will bring together six key areas designed to cater to every type of play:Kids & Toddler Play: A safe and engaging environment for younger children to explore.Sports Play: Promoting active play and physical fitness through dynamic sports activities.E-gaming and Immersive Play: Combining cutting-edge technology with play for a thrilling digital experience.Sky Play: Adventure high above the ground with elevated play areas.Water Park: A fun-filled aquatic adventure for families.Special Experiences: Unique, curated experiences that will surprise and delight visitors.In addition to these fresh and exciting concepts, PeopleUp will also introduce its popular Singapore-based attractions to Atria Shopping Gallery, tailoring them to fit the tastes and preferences of the local market.These zones will offer an all-encompassing mix of physical, mental, and sensory experiences for children of all ages, the new flagship destination will set a new standard for family entertainment in Malaysia.OSK Property’s strategic partnership with PeopleUp is a testament to the growing demand for family-centric leisure destinations in Malaysia. By combining PeopleUp's award-winning concepts with OSK Property’s vision, Atria Shopping Gallery hopes to become the top destination for families seeking fun and enriching experiences.For more information, please visit Atria Shopping Gallery’s website at www.atria.com.my and PeopleUp Singapore's website at www.peopleup.com.sg About Atria Shopping GalleryAtria Shopping Gallery is a transformation of yesterday’s beloved iconic mall in Petaling Jaya to cater to today’s more sophisticated and discerning tastes. The Shopping Gallery’s beautiful interior is inspired by the natural beauty and exquisite forms found in our tropical rainforest, creating a sense of natural opulence and an ambience that is warm and welcoming. Atria strives to offer shoppers a total experience and has in place tenants, activities and an environment that we hope will leave our shoppers feeling relaxed, inspired and enriched.About the Developer – OSK PropertyOSK Property is the property arm of the OSK Group which is a public listed company in Malaysia with an asset size over RM 10 billion. OSK Property is one of Malaysia’s leading property groups that has completed and delivered more than 50,000 properties across Malaysia and Australia. With a diverse portfolio that spans residential, commercial, hospitality, industrial and mixed-use developments, OSK Property is committed to delivering innovative and engaging spaces that enhances the way of life of communities.With each project, OSK Property continues to seek and prioritize its sustainability strategy incorporating the integration of sustainable design features, minimizing our environmental footprint by incorporating advanced technologies and infusing the natural elements such as shadow play and wind flow, and utilizing environmentally friendly materials to ensure the overall health and well-being of occupants. For further information, visit OSK Property’s website at www.oskproperty.com.myIssued By: Swan Consultancy Sdn. Bhd. on behalf of OSK PropertyFor more information, please contact:Jazzmin WanTel: +60 17-289 4110Email: j.wan@swanconsultancy.bizAsyraf HakimiTel: +60 11-23774173Email: a.hakimi@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

BOYERTOWN, Pa., Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - Global Advanced Metals (GAM), a leading global producer of metallurgical products, is pleased to announce a new partnership with the U.S. Department of Defense (DOD) to re-establish defense-critical niobium oxide production. The project, supported by a $26.4 million award from the Manufacturing Capability Expansion and Investment Prioritization directorate, leverages GAM's existing tantalum production in Boyertown, Pennsylvania.GAM LogoThe DOD's capital contribution will accelerate the development of the United States' first niobium oxide production in over 30 years. Niobium oxide is a precursor to high-purity superalloys in advanced aircraft, rocket systems, and various other defense platforms. GAM's public-private partnership forms a key component of the DOD's ongoing efforts to solidify the U.S. aerospace and defense industrial base."GAM is proud to contribute to strengthening U.S. and allied capability by mitigating supply vulnerabilities previously exploitable by our adversaries," said GAM's CEO, Andrew O'Donovan. "Every opportunity to decrease adversarial influence over defense supply chains should be taken, and we are delighted that the DOD chose to support GAM in this endeavor.""Pennsylvania has built and powered our Nation for generations, so it's no surprise that workers in Berks County will soon produce critical minerals to make the aircraft, rocket systems, and other equipment our military needs to ensure our national security," said U.S. Senator Bob Casey (D-PA). "I advocated for our Commonwealth to tackle this critical mineral risk so that we can continue the proud tradition of supporting our warfighters and the Department of Defense as a whole.""As a former chemistry teacher and Air Force officer, I've been championing efforts on critical mineral supply chains and the importance of bringing related manufacturing back to the U.S. since I first arrived in Congress," said U.S. Congresswoman Chrissy Houlahan (D-PA). "So when I visited Global Advanced Metals (GAM) in Berks County last year, I was in awe of their state-of-the-art operations - I knew GAM and companies like them have the blueprint we need to reduce reliance on countries like China for critical minerals. I'm so thrilled to hear GAM is receiving a $26.4 million award for niobium processing and manufacturing of defense-critical materials! With this federal investment, more jobs in our community will be created and our national security will be strengthened."About GAMA leading conflict-free tantalum producer, GAM has exclusive rights to the world's largest industrial resources of tantalum ore located in Western Australia.GAM produces conflict-free tantalum powders and metallurgical products at its Pennsylvania, USA and Aizu, Japan plants for a range of industries including electronics, aerospace, automotive, medical and chemical processing.GAM's smelting facilities in Japan and the USA were first declared "Conflict-Free" in 2010 under the former EICC/GeSI Conflict-Free Sourcing Initiative (CFSI) audit program and continue to maintain their conformance to the current Responsible Minerals Assurance Process (RMAP) standard.Contact InformationKurt HabeckerSr. Marketing Managerkhabecker@globaladvancedmetals.com1 610-369-8220SOURCE: Global Advanced Metals Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年9月24日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司（"本公司"，连同其附属公司统称为"本集团"或"康哲药业"）欣然宣布，磷酸芦可替尼乳膏（"芦可替尼乳膏"或"产品"）（白癜风适应症）新药上市许可申请（NDA）已于2024年9月24日获得中国国家药品监督管理局（NMPA）受理。这是产品继白癜风适应症获海南省药监局批准临床急需进口，及在澳门获批上市等系列里程碑事件之后的又一重磅进展，也是迈出惠及中国逾千万白癜风患者的关键一步。芦可替尼乳膏在中国真实世界研究中取得了积极结果。治疗组主要疗效指标第24周达到F-VASI 75的患者比例为49.5%，显著高于目标值14.1%（P<0.0001），研究达到了主要终点，证明产品能够有效治疗非节段型白癜风患者，缩小皮损面积，恢复肤色。所有的次要疗效指标均显示出与主要疗效指标一致的获益趋势，且治疗时间越长，患者的白癜风治疗效果持续改善。不良反应的严重程度大部分均为1级或2级，未发生导致停药或退出的不良事件（AE），未发生研究药物相关的严重不良事件（SAE）。在推进产品新药上市申请进程的同时，本集团针对芦可替尼乳膏的境外生产药品转移至境内生产（地产化技术转移）工作正在委托合同研发生产外包组织（CDMO）有序推进中，目前已完成小试和中试研究，正在进行放大生产。本集团争取早日完成地产化研究，在中国大陆注册并获得上市批准，让中国白癜风患者用上创新产品。白癜风是一种慢性自身免疫性疾病，其特征是皮肤色素脱失，其发病原因为产生色素的细胞即黑素细胞的缺失。据估算，中国白癜风患者约1,400万[1]。白癜风患者中约85%为非节段型白癜风。外用皮质类固醇（TCS）及钙调神经磷酸酶抑制剂（CI）均为非节段型白癜风的标签外用药，然而，这些现有外用药物疗法有长期用药的不良反应或疗效有限的临床痛点[2、3]。若中国获批上市，产品有望成为中国大陆获批的首个用于白癜风复色的处方药，将为中国广大白癜风患者带来治疗新曙光。康哲药业始终坚持以提供有竞争力的产品和服务，满足尚未满足的医疗需求为使命，在创新发展战略的指导下，不断加强自主研发与外部合作，丰富产品管线。未来，康哲药业将继续在全球范围内识别具有差异化优势的医药产品，并高效推动产品临床开发和商业化发展，为患者带来更多新药、好药。关于芦可替尼乳膏芦可替尼乳膏（Opzelura），为Incyte的JAK1/JAK2选择性抑制剂芦可替尼的创新乳膏制剂，已获得美国食品和药物管理局（FDA）批准用于12岁及以上非节段型白癜风患者的局部治疗。截至目前，芦可替尼乳膏是首个也是唯一一种在美国获批使用的白癜风复色产品[4]。此外，芦可替尼乳膏（Opzelura）在美国获批用于传统外用处方疗法不可取或不能充分控制病情之12岁及以上非免疫功能低下的轻中度AD患者的局部短期和非持续性慢性治疗[5]。芦可替尼乳膏（Opzelura）也于欧洲获批用于12岁及以上青少年及成人患者伴面部受累的非节段型白癜风的治疗[6]。虽然NMPA未批准产品在中国大陆的任何适应症药物的上市，但是产品此前于2023年8月12日获得海南省药监局批准临床急需进口，并于8月18日正式落地海南博鳌乐城国际医疗旅游先行区，用于12岁及以上青少年和成人患者伴面部受累的非节段型白癜风的局部治疗。受益于国家赋予海南自由贸易港、海南博鳌乐城国际医疗旅游先行区"先行先试"特许政策，中国白癜风患者可在博鳌超级医院先行申请使用产品并接受专家团队的治疗。此外，芦可替尼乳膏亦于2024年4月11日获得澳门政府药物监督管理局（ISAF）批准新药上市申请，用于治疗12岁及以上青少年和成人患者伴面部受累的非节段型白癜风。本集团于2022年12月2日，通过本公司附属公司-康哲美丽与Incyte就用于治疗自身免疫性炎症皮肤病的芦可替尼乳膏制剂订立合作和许可协议（"许可协议"）。根据该等许可协议，本集团通过康哲美丽获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一国（印尼、菲律宾、越南、泰国、缅甸、马来西亚、柬埔寨、老挝、新加坡、东帝汶以及文莱）（"区域"）开发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。许可协议期限开始于许可协议生效日，自产品在区域内首次商业化销售之日起拥有十年的授权期限（"授权期限"）。授权期限届满后，根据许可协议约定的特定条件，许可协议期限可延长十年（"初始延展授权期限"）。初始延展授权期限届满后，根据许可协议约定的特定条件，双方可另行协商许可协议的延长期限。Incyte拥有产品的全球开发和商业化权利，在美国和欧洲以Opzelura的名称销售。Opzelura及其logo是Incyte的注册商标。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化业务竞争力，并将皮肤医美、眼科业务独立运营，培育专科小领域的大龙头，提升专科规模效率。同时业务版图拓展至东南亚市场，着力成为全球药企进军东南亚市场的"桥头堡"，助力康哲药业高质量持续健康发展。参考文献：1、Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-72、《白癜风诊疗共识（2021版）》3、Kubelis-Lopez DE, Zapata-Salazar NA, Said-Fernandez SL, Sanchez-Dominguez CN, Salinas-Santander MA, Martinez-Rodriguez HG, Vazquez-Martinez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.4、FDA批准信息可在FDA官网查询，网址如下：https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older5、FDA批准信息可在incyte官网查询，网址如下：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream6、EMA批准信息可在EMA官网查询，网址如下：https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及本集团的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。本集团并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，本集团对该等第三方声明及预测不承担责任。 Copyright 2024 亚太商讯 via SeaPRwire.com.

QUAKERTOWN, PA, Sept 24, 2024 - (ACN Newswire via SeaPRwire.com) - At the start of 2024, DEXIS introduced its digital ecosystem, a suite of tools and software designed to connect and streamline the implant workflow from diagnosis to delivery.Today, DEXIS announced upgrades across the ecosystem to aid clinicians in important workflow elements from visualizing progressive dental issues to designing chairside surgical guides."Our technology makes it easy to organize information and execute treatments, which is at the core of what clinicians expect from us," said DEXIS President, Robert Befidi. "We are connecting and standardizing the implant workflow while also constantly evaluating our efforts to ensure we provide deeper patient insights and flexible, intuitive solutions that reduce complexity. These three launches are a good example of our focus on continuous innovation across the ecosystem to deliver diagnostic confidence, productivity, and smart simplicity."A brand-new X-ray platform is now available, designed specifically for general practitioners looking to expand their diagnostic capabilities with 3D imaging. Developed and produced in Tuusula, Finland, the ORTHOPANTOMOGRAPH™ OP 3D™ EX captures consistently accurate images through a straightforward, easy-to-learn workflow. The unit has a wide range of field of view sizes to support multiple clinical indications, including implant placement, endodontics, periodontics, and analysis for airway and TMJ. Early adopters of the OP 3D EX have reported positive feedback:"When choosing a CBCT, the key factors for me were a large sensor, predictable acquisition, stellar image quality and intuitive software that wouldn't interrupt my workflow," says Dr. Tyler Tolbert of Smile Now Dental Group. "Once the OP 3D EX got here and we started taking some scans, I thought to myself, ‘We really made the right choice here!'"In addition to new hardware, a brand-new software release will provide advanced tools to plan and execute same-day, prosthetically driven implants.Serving as the unifying software and central hub of the ecosystem, DTX Studio™ Clinic stores and manages all patient data as well as helps clinicians execute each step of the implant process from diagnostics to delivery.The software's new functionality allows practitioners to plan an implant treatment and generate a surgical guide chairside - all in less than three minutes. Clinicians can virtually extract teeth, adjust photorealistic abutments and crowns, and create an automated surgical guide that can be sent to a lab or produced in-house for same-day delivery."We were able to implement the OP 3D EX quickly and start taking scans largely due to the included DTX Studio Clinic software," said Dr. Nicholas Varney of Varney Dental. "Once we got going, we found that so much of the work involved in prepping a 3D scan for confident diagnosis was done by the software automatically. DTX Studio Clinic has improved how we work in all aspects - communicating with patients, implant planning and even treatment team collaboration."In addition to 3D imaging enhancements, an intraoral scanning software update offers scan quality and usability improvements as well as clear visualizations of progressive dental issues over time, through a new tool called Oral Compare. Additionally, the software's new integration with SmileFy allows for the ability to simulate treatment outcomes chairside, giving patients further confidence in proposed treatment plans.To learn more about DEXIS and the latest implant workflow upgrades, visit https://www.dexis.com.About DEXISDEXIS is the global leader in dental imaging. We bring together the most trusted brands in 2D and 3D imaging, intraoral scanning solutions, and diagnostic software, in one connected and AI-powered ecosystem. Our innovative and award-winning technologies use smart simplicity to increase productivity and enhance diagnostic confidence. For more information, please visit dexis.com.About Envista Holdings CorporationEnvista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide array of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.Contact InformationMaria PenalozaMedia & Content Strategy Managermaria.penaloza@issuerdirect.comSOURCE: DEXIS Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, Sept 24, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). This is another substantial milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval for marketing in Macau for vitiligo, and it is also a key step in benefiting over ten million of patients with vitiligo in China.Ruxolitinib cream achieved positive results in Chinese Real-World Study. The primary efficacy endpoint was the proportion of patients in the treatment group who achieved F-VASI 75 response at week 24, which was 49.5%, significantly higher than the target value of 14.1% (p<0.0001). The study met its primary endpoint, demonstrating that ruxolitinib cream is effective in treating patients with nonsegmental vitiligo, reducing the area of the lesions, and repigmenting the skin. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.While advancing the process of NDA for the Product, the Group is conducting the transfer of ruxolitinib cream from overseas production to domestic production (localization technology transfer), which is being orderly promoted by the Contract Development Manufacturing Outsourcing Organization (CDMO), and the lab-scale and pilot trial studies have been completed and under scale-up production. The Group strives to complete the localization study as soon as possible, register in Mainland China and obtain marketing approval, so as to enable the Chinese patients with vitiligo to use the innovative product.Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[1]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[2,3]. If the Product being successfully approved for marketing in China, it will be the first prescription drug approved for repigmentaton in vitiligo in Mainland China, bringing novel treatment hopes for Chinese vitiligo patients.CMS has always adhered to its mission of providing competitive products and services to meet unmet medical needs. Guided by innovation strategy, the Group continuously strengthens its independent R&D as well as external collaboration, enriching its product pipelines. Looking ahead, CMS will continue to identify products with differentiated advantages globally and efficiently promote their clinical development and commercialization, bringing more novel and effective drugs to patients.About ruxolitinib creamRuxolitinib cream, (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, and is the first and only treatment for repigmentation approved for use in the United States[4]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[5]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[6].The Product is not approved by the NMPA for any indication in Mainland China. However, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”) on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. In addition, ruxolitinib cream was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024 for the topical treatment of non-segmental vitiligo with facial involvement in adult and adolescents form 12 years of age.On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the  License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference：1 Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-72 Consensus on the diagnosis and treatment of vitiligo (2021 version)3 Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.4 Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older 5 Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 6 Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Sept 24, 2024 - (ACN Newswire via SeaPRwire.com) – Hong Kong traders remain optimistic about their prospects with a sustained period of moderate growth believed to be underway. This was the key finding of the Hong Kong Trade Development Council (HKTDC) Export Confidence Index for the third quarter of 2024 as released today.The Index – a quarterly review of the views and expectations of Hong Kong-based traders across a broad cross-section of industry sectors – showed that, despite a slight decline compared to the second quarter, underlying sentiment remains broadly positive. In another welcome outcome, the majority of the sub-indices remained in expansionary territory, a clear indication of widespread anticipation of continued growth.Putting the overall findings into context, Irina Fan, Director of HKTDC Research, said: “Hong Kong exporters remain resilient, despite the uncertainty stemming from lingering trade tensions. Indeed, the majority of respondents reported no – or only minimal – impact from the recent round of trade restrictions and higher tariffs.”Strong sales and new ordersLooking at the findings in greater detail, the overall Current Performance Index rose by 1 point to 52.6, a development seen as reflecting strong sales and new orders, rising unit prices and expanding procurement activities. This was underlined by concurrent rises in the relevant Sub-Indices – the Trade Value Sub-Index (56.2, +2.5) and Procurement Sub-Index (57.3, +3.3). Although the Sales & New Orders Sub-Index recorded a moderate 1.8-point drop, it stayed resolutely in expansionary territory at 55.7.The Expectation Index also remained in expansionary territory at 51.4 even after a 2.9-point dip. This decrease was driven mainly by the 8.5-point decline in the Trade Value Expectation Sub-Index (down to 51.7), with traders expecting unit prices to increase only moderately.The same traders, however, remained optimistic about the outlook for sales and new orders (with a Sales & New Orders Expectation Sub-Index reading of 54.6); and look set to continue to expand their procurement activities (Procurement Expectation Sub-Index: 55.4).Overall, the findings suggest that the immediate future will be characterised by moderate, sustained export growth.Cost pressures lessen, but remain major concernIt was also apparent that costs remained the major drag on exporter confidence in the third quarter. While both the Current and Expectation Cost Sub-Index showed some improvement, scores remained at about the 35 level, an indication that exporters are still facing strong cost pressures.In terms of Current Performance, exporters have seen increased Sales and New Orders across all their key markets. With regard to outlook (Expectation), exporters were most upbeat about the ASEAN bloc (59.7) and mainland China (58.4).By industry, the third quarter saw an improvement in Current Performance across all sectors. In terms of prospects for the near-term, Clothing exporters are the most optimistic at 61.2, followed by Toys (58.7) and Jewellery (56.4).Looking to the immediate future, Nicholas Fu, Senior Economist with HKTDC Research, said: “Exporters from five out of the six key sectors expect the current positive business momentum to continue. Overall, Clothing exporters were the most upbeat, followed by those in the Toys and Jewellery sectors. While it is noteworthy that cost pressures are expected to stay high across all sectors, there is some possibility of a slight improvement further down the line.”In addition to addressing the standard index criteria, the latest survey also focused on several specific thematic questions with regard to the primary challenges facing exporters and the favoured forward strategies of participants. Responses here showed that:- High and rising costs (transport, labour, production and capital) were seen as the most significant challenges.- In order to mitigate any related risks, Hong Kong exporters intend to adopt more cautionary business strategies.- Regarding the impact of recent trade restrictions and higher tariffs on certain China-origin exports, 60% of respondents reported no impact on their business to date, while 39% expect only a moderate downside.- On the sustainability front, however, fewer than 20% of respondents were familiar with the EU's newly enacted Ecodesign for Sustainable Products Regulations (ESPR), which is expected to have a broad impact across many industry sectors.Notes for EditorsThe HKTDC Export Confidence Index was introduced in the first quarter of 2024. It is a composite of five sub-indices – Sales and New Orders, Trade Value, Cost, Procurement and Inventory – and seeks to provide a comprehensive overview of Hong Kong exporter sentiment.There are two primary / overall indices, one of which gauges the Current Performance in the present quarter, while the other considers the Expectation for the upcoming quarter via a weighted average of the following five sub-indices:- Sales and New Orders: This is an indication of overall export performance as well as the level of new export orders received by respondents. This index is compiled based on respondents' feedback regarding the prospects of each of their major export markets.- Trade Value: This focuses on tracking the movement of unit export prices.- Cost: This tracks cost pressures as they relate to day-to-day operations, including raw material prices / labour and other operational costs/ financing requirements. Compared with the other indices, it is an inverted index, with an index reading above 50 indicating a downward trend for costs, while a reading below 50 indicates an upward trend for costs.- Procurement: This is a measure of the input-buying activity of Hong Kong traders.- Inventory: This tracks the overall inventory levels held by respondents for present use and the upcoming quarter. An index reading above 50 indicates a lower-than-normal inventory level, while a reading below 50 indicates a higher-than-normal inventory level.To view this press release in Chinese, please visit http://mediaroom.hktdc.com/tcReferences- HKTDC Research website: http://research.hktdc.com/- HKTDC Export Confidence Index 3Q24: Sustained Optimism Underpinned by Strong Sales and New Orders https://research.hktdc.com/en/article/MTgwNDk1NTM5OQPhoto download: https://bit.ly/4deCzLZHKTDC Director of Research Irina Fan (left) and Senior Economist Nicholas Fu (right) announced the HKTDC Export Confidence Index for the third quarter of 2024 at a press conference todayHKTDC Director of Research Irina FanHKTDC Senior Economist Nicholas FuMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2024 ACN Newswire via SeaPRwire.com.

MUNICH, GERMANY & TEL AVIV, ISRAEL, Sept 24, 2024 - (ACN Newswire via SeaPRwire.com) - Autobrains, a global leader in AI-powered automotive solutions, is pleased to unveil its latest innovation: Air2Road, a breakthrough localization technology developed to enhance the capabilities of Advanced Driver Assistance Systems (ADAS) and Autonomous Driving solutions. Powered by Autobrains' Liquid AI Technology, Air2Road delivers precise, real-time vehicle localization for safe and efficient navigation, even in challenging conditions such as occlusions, adverse weather, and complex urban environments.Autobrains' Air2Road Localization TechnologyFusing aerial images with ground images for highly precise and reliable localization.As the automotive industry accelerates toward fully autonomous vehicles, reliable and accurate localization is crucial for determining both vehicle position and the driving environment. Traditional localization systems, heavily reliant on Global Navigation Satellite Systems (GNSS) or crowd-sourced maps, face significant challenges such as limited coverage, high costs, and susceptibility to interference. Additionally, these systems rely on a single source of sensor-based information, leading to frequent errors and over-reliance on one type of input during driving."Air2Road is a game-changer for autonomous driving technology," said Igal Raichelgauz, CEO and Founder of Autobrains. "By providing multimodal redundancy and unmatched precision, Air2Road pushes the boundaries of what's achievable in vehicle navigation and safety, ensuring autonomous systems operate reliably under even in the most challenging conditions."Air2Road sets a new standard for vehicle localization by combining Signatures derived from two independent modalities - aerial imagery and ground-based perception - ensuring multimodal redundancy and accuracy. These Signatures are sparse binary hyperdimensional representations of both the driving environment and objects within it. This innovative approach overcomes many of the limitations inherent in traditional systems. These include:Multimodal Redundancy: By creating a joint representation of Signatures from two independent modalities (aerial images and ground-based data), Air2Road enables an unprecedented advantage of multimodal redundancy. Other existing systems use a fleet of vehicles with similar ground-based data sources, which increases repetitive mistakes and dependency on a single source of information.Full coverage: Unlike GNSS-based systems, Air2Road, with its Signature-based technology, continues to function effectively even under trees, bridges, between buildings, and in any other scenario with bad reception of the GNSS signal.Aerial Perception: Aerial images generate additional data layers-such as road markings, traffic signs, and obstacles-enabling safer and more efficient driving decisions and a redundancy to real-time perception.Scalable and Efficient: Traditional localization systems, such as crowd-sourced maps, require a fleet of vehicles to repeatedly traverse roads for data harvesting and building the map before the localization service becomes available for any vehicle. In contrast, Air2Road, enables the first vehicle on the road to achieve precise localization instantly, ensuring scalable deployment across various regions without compromising accuracy.Cost-Effective: Air2Road is compatible with affordable aerial imagery from multiple vendors, and its compressed Signatures technology enables large areas to be stored directly on the vehicle. This allows for a low-memory, low-bandwidth system, eliminating the need for constant cloud connectivity.Environment-Aware Path Planning: By leveraging real-time data on road conditions, traffic flow, and parking areas, Air2Road supports safer, more optimized navigation.Inspired by the human brain's ability to process multisensory information, Air2Road replicates mechanisms such as situational awareness and attention focus to ensure accurate decision-making. By filtering out irrelevant data and focusing on critical elements like road edges and buildings, the system significantly improves localization precision.With its data-driven approach and revolutionary dual-modality technology, Air2Road is poised to redefine the future of localization, facilitating safer and more reliable autonomous driving solutions.For more information about Autobrains and its cutting-edge Liquid AI and ADAS solutions, please visit autobrains.ai.Contact InformationSophia EichlerDirector of Marketingmedia@autobrains.ai+49 15167066494SOURCE: Autobrains Copyright 2024 ACN Newswire via SeaPRwire.com.

Highlights:An additional two (2) drill holes for approximately 1,188.1 metres (m) were completed during the Summer 2024 Drill Campaign and reported herein.Drill hole CS24-022 encountered 14 spodumene-pegmatite intervals, with the widest continuous interval of 52.3 m.Drill hole CS24-023 encountered 15 spodumene-pegmatite intervals, with the widest continuous interval of 188.6 m.Vancouver, BC, Sept 24, 2024 - (ACN Newswire via SeaPRwire.com) - Q2 Metals Corp. (TSXV:QTWO)(OTCQB:QUEXF)(FSE:458) ("Q2" or the "Company") is pleased to provide an update on the Summer 2024 Drill Program at the Cisco Lithium Property (the "Property" or the "Cisco Property") located within the greater Nemaska traditional territory of the Eeyou Istchee James Bay region of Quebec, Canada.The Summer 2024 Drill Campaign at the Cisco Lithium Property has concluded with a total of five (5) drill holes for approximately 2,609.9 m completed. Since May 2024, the Company has drilled a total of 6,359.7 m over 17 holes. All drill holes intercepted pegmatite with visual indications of spodumene mineralization identified."To say it's been a very productive first drill season for Q2 Metals at our Cisco Lithium Property is an understatement," said Q2 Metals President and CEO Alicia Milne. "The property continues to deliver, and we are pleased with what we're seeing and are eagerly awaiting the results from the now 13 drills holes that are yet to be reported.""We have been incredibly fortunate to be able to have built as much value in an early-stage project in four months. We have just started on the Cisco Project and look forward to receiving the assays on the holes drilled as we continue to move forward with Cisco," said Q2 Metals VP of Exploration Neil McCallum.The Summer 2024 Drill Campaign was focused on exploring the connection of the wide, continuous pegmatite zones that were encountered in holes CS24-010, CS24-018 and CS24-021. The last two holes of the season continued to confirm and expand the understanding of the main pegmatite zone.The geological team has completed the core cutting and logging of the last two (2) drill holes (CS24-022 to 023) of the Summer 2024 Campaign and the samples have been dispatched to the SGS Canada preparation laboratory located in Val-d'Or, QC for mineral analysis to confirm the presence of lithium. The visual results of drill holes CS24-022 and CS24-023 are herein reported.Summer 2024 Drilling UpdateFigure 1. Map of Drilling area, Cisco PropertyDrill hole CS24-022 was drilled on the same line as hole CS24-018 and collared 200 metres behind it, encountering 14 individual spodumene pegmatite intervals. Nine (9) intervals were greater than 10 m wide, with the widest individual interval measuring 52.3 m.CS24-023 was drilled at the same collar location as hole CS24-020 in order to test the southern strike direction of the main large continuous pegmatite zone. Drill hole CS24-023 encountered 15 individual spodumene pegmatite intervals of which eight (8) intervals were greater than 10 m wide, with the widest individual interval measuring 188.6 m.Table 1. Summary of Spodumene-Pegmatite intervals, Cisco PropertyFigure 2. Visual photo mapping the distance between hole CS24-023 and the CO1 outcrop measuring; 850 mTable 2. Summary of Drill Hole Collar Information, Cisco Property (CS24-022 to 023)The mineralized intervals in all the holes are not necessarily representative of the true width and the modelled pegmatite zones are being refined with every additional hole.Cautionary Statement: The presence of pegmatites does not confirm the presence of lithium (spodumene or other lithium minerals). Pegmatites are fractionated coarse grained igneous rocks commonly associated with lithium mineralization; however, many pegmatites do not contain mineralization. The presence of any mineralization can only be confirmed with assaying.About the Cisco PropertyThe Cisco Property is comprised of 222 mineral claims and is 11,374 hectares in size. It is located less than 10 km east of the Billy Diamond Highway, and is approximately 150 km north of Matagami, a small town that contains the closest rail link to much of James Bay. The Property lies within the greater Nemaska Community lands of the Eeyou Istchee Territory, James Bay, Quebec.The Property is situated along the Frotet Evans Greenstone Belt, comprised of a volcanic package dominated by mafic to felsic metavolcanic rocks, of the southern James Bay Lithium District, the same belt that hosts the Sirmac and Moblan lithium deposits, located 130 km and 180 km away, respectively.Sampling, Analytical Methods and QA/QC ProtocolsAll drill core samples are shipped to SGS Canada's preparation facility in Val D'Or, Quebec, for standard sample preparation (code PRP92) which includes drying at 105°C, crushing to 90% passing 2 mm, riffle split 500 g, and pulverize 85% passing 75 microns. The pulps are then shipped by air to SGS Canada's laboratory in Burnaby, BC, where the samples are homogenized and subsequently analyzed for multi-element (including Li and Ta) using sodium peroxide fusion with ICP-AES/MS finish (code GE_ICM91A50). The reported Li grade will be multiplied by the standard conversion factor of 2.153 which results in an equivalent Li2O grade. Drill core was saw-cut with half-core sent for geochemical analysis and half-core remaining in the box for reference. The same side of the core was sampled to maintain representativeness.A Quality Assurance / Quality Control (QA/QC) protocol following industry best practices was incorporated into the sampling program. Measures include the systematic insertion of quartz blanks and certified reference materials (CRMs) into sample batches at a rate of approximately 5% each. Additionally, analysis of pulp-split and reject-split duplicates was completed to assess analytical precision. The QP has verified the QA/QC results of the analytical work.Qualified PersonNeil McCallum, B.Sc., P.Geol, is a registered permit holder with the Ordre des Géologues du Québec and Qualified Person as defined by NI 43-101 and has reviewed and approved the technical information in this news release. Mr. McCallum is a director and VP Exploration for Q2.About Q2 Metals CorpQ2 Metals is a Canadian mineral exploration company focused on unlocking its portfolio of lithium projects in the Eeyou Istchee James Bay region of Quebec, Canada, that includes both its 100-per-cent-owned Mia Lithium Property and the Cisco Lithium Property.The Cisco lithium property is located approximately 150 km north of Matagami, Que., and comprises 222 mineral claims and is 11,374 ha in size. The property has district-scale potential with an already identified mineralized zone and a discovery drill result that included 120.3 metres at 1.72% lithium oxide (hole CS-23-010).FOR FURTHER INFORMATION, PLEASE CONTACT:Alicia MilnePresident & CEOAlicia@Q2metals.comTelephone: 1 (800) 482-7560E-mail: info@Q2metals.comJason McBrideCorporate CommunicationsJason@Q2metals.comWWW.Q2Metals.comFollow the Company: Twitter, LinkedIn, Facebook, and InstagramForward-Looking StatementsThis news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian legislation. Forward-looking statements are typically identified by words such as: "believes", "expects", "anticipates", "intends", "estimates", "plans", "may", "should", "would", "will", "potential", "scheduled" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Accordingly, all statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, any statements or plans regard the geological prospects of the Company's properties and the future exploration endeavors of the Company. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions.Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date specified in such statement. Forward looking statements in this news release include, but are not limited to, drilling results on the Cisco Property and inferences made therefrom, the potential scale of the Cisco Property, the focus of the Company's current and future exploration and drill programs, the scale, scope and location of future exploration and drilling activities, the Company's expectations in connection with the projects and exploration programs being met, the Company's objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, variations in ore grade or recovery rates, changes in project parameters as plans continue to be refined, unsuccessful exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same. Readers are cautioned that mineral exploration and development of mines is an inherently risky business and accordingly, the actual events may differ materially from those projected in the forward-looking statements. Additional risk factors are discussed in the section entitled "Risk Factors" in the Company's Management Discussion and Analysis for its recently completed fiscal period, which is available under Company's SEDAR profile at www.sedarplus.ca.Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.SOURCE: Q2 Metals Corp. Copyright 2024 ACN Newswire via SeaPRwire.com.